Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 160Peripheral Blood Stem Cell Transplantation 85fludarabine phosphate 81Filgrastim 78Methotrexate 69Etoposide 68Cytarabine 62Rituximab 61Radiotherapy 56Cyclosporine 52Mycophenolic Acid 51Vincristine 50Whole-Body Irradiation 48Busulfan 46Tacrolimus 41Antilymphocyte Serum 40Melphalan 39Dexamethasone 39Prednisone 36Methylprednisolone 35Doxorubicin 35fludarabine 28Granulocyte Colony-Stimulating Factor 25Calcium Dobesilate 25merphos 24Leucovorin 23Cord Blood Stem Cell Transplantation 22sargramostim 18dexamethasone acetate 18dexamethasone 21-phosphate 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × BI 2536 × Other hematologic neoplasm × Clear all
NCT00243087 2024-12-20

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Boehringer Ingelheim

Phase 1 Completed
41 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡